tiprankstipranks
Paradigm Biopharmaceuticals Ltd. (PBIGF)
OTHER OTC:PBIGF

Paradigm Biopharmaceuticals Ltd. (PBIGF) Stock Price & Analysis

9 Followers

PBIGF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.16 - $0.76
Previous Close$0.19
Volume80.00K
Average Volume (3M)15.57K
Market Cap
$54.72M
Enterprise Value$29.64M
Total Cash (Recent Filing)AU$39.67M
Total Debt (Recent Filing)AU$616.67K
Price to Earnings (P/E)-1.2
Beta0.96
Aug 23, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding350,297,509
10 Day Avg. Volume8,250
30 Day Avg. Volume15,570
Standard Deviation0.35
R-Squared0.05
Alpha-0.00328
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Paradigm Biopharmaceuticals Ltd. News

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

8.17%2.29%0.38%89.16%
0.38% Other Institutional Investors
89.16% Public Companies and
Individual Investors

PBIGF FAQ

What was Paradigm Biopharmaceuticals Ltd.’s price range in the past 12 months?
Paradigm Biopharmaceuticals Ltd. lowest stock price was $0.16 and its highest was $0.76 in the past 12 months.
    What is Paradigm Biopharmaceuticals Ltd.’s market cap?
    Currently, no data Available
    When is Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date?
    Paradigm Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 23, 2024 which is in 120 days.
      How were Paradigm Biopharmaceuticals Ltd.’s earnings last quarter?
      Paradigm Biopharmaceuticals Ltd. released its earnings results on Feb 28, 2024. The company reported -$0.105 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.105.
        Is Paradigm Biopharmaceuticals Ltd. overvalued?
        According to Wall Street analysts Paradigm Biopharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Paradigm Biopharmaceuticals Ltd. pay dividends?
          Paradigm Biopharmaceuticals Ltd. does not currently pay dividends.
          What is Paradigm Biopharmaceuticals Ltd.’s EPS estimate?
          Paradigm Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Paradigm Biopharmaceuticals Ltd. have?
          Paradigm Biopharmaceuticals Ltd. has 309,932,280 shares outstanding.
            What happened to Paradigm Biopharmaceuticals Ltd.’s price movement after its last earnings report?
            Paradigm Biopharmaceuticals Ltd. reported an EPS of -$0.105 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.348%.
              Which hedge fund is a major shareholder of Paradigm Biopharmaceuticals Ltd.?
              Currently, no hedge funds are holding shares in PBIGF
              ---

              Paradigm Biopharmaceuticals Ltd. Stock Smart Score

              3
              Underperform
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -74.34%
              12-Months-Change

              Fundamentals

              Return on Equity
              -124.58%
              Trailing 12-Months
              Asset Growth
              -48.80%
              Trailing 12-Months

              Company Description

              Paradigm Biopharmaceuticals Ltd.

              Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company which engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic rhinitis.
              ---

              PBIGF Stock 12 Months Forecast

              Average Price Target

              {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2022","6":"Jan<br/>2023","9":"Apr<br/>2023","12":"Jun<br/>2023","25":"Jun<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.4984615384615385,0.456923076923077,0.4153846153846154,0.3738461538461539,0.33230769230769236,0.2907692307692308,0.24923076923076926,0.20769230769230773,0.1661538461538462,0.12461538461538468,0.0830769230769231,0.04153846153846158,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.4984615384615385,0.456923076923077,0.4153846153846154,0.3738461538461539,0.33230769230769236,0.2907692307692308,0.24923076923076926,0.20769230769230773,0.1661538461538462,0.12461538461538468,0.0830769230769231,0.04153846153846158,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.4984615384615385,0.456923076923077,0.4153846153846154,0.3738461538461539,0.33230769230769236,0.2907692307692308,0.24923076923076926,0.20769230769230773,0.1661538461538462,0.12461538461538468,0.0830769230769231,0.04153846153846158,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.64,"date":1656633600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.86,"date":1659312000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.11,"date":1661990400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.79,"date":1664582400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.92,"date":1667260800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.93,"date":1669852800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.94,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.92,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.87,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.73,"date":1681430400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
              Similar Stocks
              Company
              Price & Change
              Follow
              Puma Biotechnology
              Brainstorm Cell Therapeutics
              Karyopharm Therapeutics
              BioMarin Pharmaceutical
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis